SynthesisFrontiers in endocrinology2026
Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma: a simplified risk scoring system.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In line with current guidelines, risk stratification in papillary thyroid microcarcinoma (PTMC) has shifted from simple diameter-based assessments to evaluation of individual tumor biology. Therefore, this study aimed to investigate how baseline clinical and molecular risk factors influence aggressive PTMC phenotypes. Methods: Registered in PROSPERO (CRD42024603662), we searched PubMed, Embase, and Cochrane through February 14, 2025. We analyzed risk factors for lymph node metastasis (LNM) and extrathyroidal extension (ETE) utilizing data from surgical cohorts of patients with PTMC, calculating pooled odds ratios (OR) and 95% confidence intervals (CI). Results: A total of 274 articles we found increased odds of central lymph node metastasis (CLNM) associated with male sex (OR = 1.86; CI:1.73-2.00), age (<45 and <55 years old OR = 1.61; CI:1.42-1.83 and OR = 1.89; CI:1.71-2.09), tumor size (>5 and >7 mm OR = 2.26; CI:2.00-2.56 and OR = 1.81; CI:1.11-2.96), multifocality (OR = 1.96; CI:1.78-2.16), bilaterality (OR = 1.70; CI:1.45-2.00) and BRAFV600E mutation (OR = 1.51; CI:1.25-1.82). Lateral lymph node metastasis (LLNM) was associated with male sex (OR = 1.69; CI:1.51-1.90), age (<45 and <55 years old OR = 1.5; CI:1.28-1.76 and CI:1.31-1.72), tumor size (>5 mm and >7 mm, OR = 2.34; CI:1.68-3.25 and OR = 3.71; CI:3.15-4.36), multifocality (OR = 1.98; CI:1.46-2.70) and bilaterality (OR = 1.91; CI:1.22-3.00). For ETE, risk factors were as follows: tumor size (>5 mm OR = 3.00; CI:2.03-4.45), multifocality (OR = 2.41; CI:1.99-2.91), bilaterality (OR = 2.58; CI:1.26-5.27), and BRAFV600E mutation (OR = 2.19; CI:1.61-2.97). Conclusion: Male sex, age (<45 and <55 years), tumor size (>5 mm), multifocality, bilaterality, and BRAF Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024603662, identifier CRD42024603662.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.